CAI · Caris Life Sciences, Inc. · Stock research

Current Thesis

The narrative leg being bought is a molecular-profiling platform crossing from cash-burning growth story to self-funding compounder while the product surface widens from tissue into blood. The 2026-08-05 Q2 print carried total revenue of $263.7M (+45% YoY) against a $238.125M consensus, positive adjusted EBITDA of $55.7M, positive free cash flow of $6.4M, a GAAP net loss narrowed to $0.6M, and a full-year 2026 revenue guide lifted to $1.030–1.040B from $1.000–1.020B (27–28% growth) versus a $1.003B estimate.

That print is what the three-month move is priced on. The 2026-08-21 close of $26.27 is 68.9% above the level of three months prior and still 33.2% under the $39.30 52-week high, with RSI(14) at 82.6. The fundamental leg is intact and freshly confirmed; the entry tension is the problem, because the tape has run through the Street's median 12-month target and the next dated company event is roughly ten weeks out.

Life-cycle: ACCELERATING. What dates it: the beat-and-raise landed 2026-08-05, target revisions followed 2026-08-06 and 2026-08-07 (Evercore ISI to $26 from $25; BTIG to $33 from $32; Bank of America reiterating Buy), the Caris Detect multi-cancer early-detection launch was 2026-07-01, and the PTEN immunohistochemistry addition for metastatic prostate cancer was 2026-07-14. Attention is expanding into a name with a ~14-month public record. The counterweight — price above the median posted target — is a crowding observable inside an accelerating leg, not yet evidence of a saturated one.

Bullish and bearish views on Caris Life Sciences, Inc.

The model's bull view on Caris Life Sciences, Inc. (CAI), in brief: Q2 2026 (reported 2026-08-05): total revenue $263.7M, +45% YoY, beating the $238.125M consensus; molecular profiling services revenue $252.3M, +55% YoY. The bear view: The price is through the Street. stockanalysis.com shows an average 12-month target of $27 and a median of $26.50 against the 2026-08-21 close of $26.27. The post-print revisions were incremental — $25 to $26 at Evercore ISI, $32 to $33 at BTIG — so the target moves followed the… Both cases follow in full.

Bull Case

• Q2 2026 (reported 2026-08-05): total revenue $263.7M, +45% YoY, beating the $238.125M consensus; molecular profiling services revenue $252.3M, +55% YoY.
• Growth is price-led as well as volume-led. Roughly 59,200 clinical cases in Q2, +18% YoY (about 48,300 MI Profile and 10,700 Caris Assure), against +45% revenue growth, on a record blended average selling price above $3,850. Revenue expanding at more than twice the case-count rate is a reimbursement-mix outcome, and mix is the harder thing for a competitor to copy.
• Margin inflection is measured, not projected. Gross margin reached 68% in Q2, roughly 5 points better than the year-ago quarter, alongside $55.7M of adjusted EBITDA and $6.4M of free cash flow.
• Guidance moved up, not just the quarter. FY2026 revenue guidance to $1.030–1.040B on 2026-08-05, from $1.000–1.020B.
• Payer footprint disclosed at the Q2 call: 239.5 million covered lives for MI Cancer Seek and 131.9 million for Caris Assure, with management targeting 200 million covered lives for Assure by year-end 2026.
• Product cadence through 2026: Caris Detect commercial launch 2026-07-01; PTEN IHC for metastatic prostate cancer 2026-07-14 following FDA approval of a PTEN biomarker-guided therapy and its companion diagnostic; ChromaSeeq and MI Clarity V2 launched in the period; an MRD assay guided for launch in 2H 2026.
• Capital return from a recent IPO: the board authorized up to $100M of repurchases with no expiration (2026-06-08), carried again with the Q2 release.

Bear Case

• The price is through the Street. stockanalysis.com shows an average 12-month target of $27 and a median of $26.50 against the 2026-08-21 close of $26.27. The post-print revisions were incremental — $25 to $26 at Evercore ISI, $32 to $33 at BTIG — so the target moves followed the tape rather than opened room above it.
• Two posted targets sit below spot: J.P. Morgan Buy at $25 (2026-08-06) and Piper Sandler Hold at $21 (2026-08-06).
• RSI(14) at 82.6 on 2026-08-21. Momentum this stretched has no bearing on the business and every bearing on the price paid for it.
• The 2025 de-rate is the memory. The shares remain 33.2% below the $39.30 52-week high; whatever reset the multiple then has not been re-earned in price.
• Profitability is an adjusted figure. GAAP net loss was $0.6M in Q2 and free cash flow $6.4M for the quarter, against a $100M repurchase authorization — the buyback is not funded out of the quarter's cash generation.
• Reimbursement is the single largest swing factor. Management described Caris Assure as still moving through New York State review at the Q2 call. An ASP above $3,850 is the number that converts case volume into revenue; a payer rate change hits the top line directly.
• Macro backdrop for long-duration diagnostics: on 2026-08-20 long-end Treasury yields snapped back toward 20-month highs, with the Dow down about 300 points and Walmart off 9% in the same session.
• No confirmed company catalyst inside 30 days. The next scheduled datapoint is the Q3 print, and Q2 landed 2026-08-05.

Setup & Price Structure

The 2026-08-05 print is the structural pivot; everything in the current price references it. The 2026-08-21 close of $26.27 sits in the overhead band formed by the cluster of posted targets — $25 (J.P. Morgan), $26 (Evercore ISI), a $26.50 median — with BTIG's $33 the only recently raised target materially above the tape. Between spot and the $39.30 52-week high there is 33.2% of unrecovered ground, and the trading record only extends back to the 2025 Nasdaq listing, so there is no multi-year shelf to lean on.

Crowding observables, stated as observables: RSI(14) of 82.6 on 2026-08-21 after a 68.9% three-month advance; price above the median analyst target; five sell-side actions clustered into 2026-08-06 and 2026-08-07 immediately behind the print; no earnings date inside the next 30 days to reset expectations either way. The company dual-listed on NYSE Texas on 2026-06-16 while keeping Nasdaq primary, which splits reported venue volume. Recent filings show no secondary issuance into this strength as of 2026-08-22 — an S-1 or shelf takedown appearing here would be a material change to the supply picture.

Catalyst Calendar (next 30 days)

• 2026-08-22 → 2026-09-21: no company-confirmed event. Nothing scheduled by Caris falls inside the window as of 2026-08-22. This is the flat part of the calendar.
• ~2026-11-04 (est.): Q3 2026 results. Q2 was reported 2026-08-05; the date is unconfirmed. This is the next real binary: whether FY26 guidance moves above $1.040B and whether blended ASP holds above $3,850.
• By 2026-12-31 (guided 2H 2026): commercial launch of the Caris MRD assay.
• By 2026-12-31 (management target, stated 2026-08-05): Caris Assure covered lives reaching 200 million, from 131.9 million at the Q2 call.

Elapsed catalysts

• ~September 2026 (est.): the annual September healthcare investor-conference season (Morgan Stanley, Baird, Wells Fargo). Caris participation had not been announced as of 2026-08-22 — treat as unscheduled, not as a catalyst. (passed 1d ago)

What Would Change Our Mind

The reimbursement leg is the load-bearing one. If the blended average selling price stops climbing above $3,850 at the Q3 print, the gap between +45% revenue growth and +18% case growth closes, and the story becomes a volume-limited 18% grower priced as a 45% one. Second, if the FY26 range is merely reiterated at $1.030–1.040B instead of raised again, the beat-and-raise cadence that produced the three-month re-rate has ended and the November print becomes the date that came and went. Third, an adverse coverage decision on Caris Assure, or an equity or convertible issuance filed into this strength, would change the supply-and-funding picture that the $100M repurchase authorization currently implies.

On price, the thesis-break condition is a weekly close below $22 — beneath the J.P. Morgan $25 and Evercore ISI $26 marks and within a dollar of the lowest posted target on the Street ($21, Piper Sandler, Hold, 2026-08-06). A move of that size unwinds the post-print re-rate and would mean the market rejected a beat-and-raise, which is a different fact pattern than a momentum name cooling off.

A secondary condition: the theme flipping to SATURATED — no new initiations or targets above $33 while retail-sentiment coverage clusters and price stalls under the $26.50 median target — would remove the incremental bid without any fundamental datapoint changing.

Correlation Notes

• Precision-oncology / AI-diagnostics complex. Trades in sympathy with Tempus AI (TEM, which appeared in the 2026-08-20 large-cap movers list), Natera, Guardant Health and Exact Sciences. Sector-wide reimbursement headlines move all of them together regardless of company-specific results.
• Rate duration. A loss-making-on-GAAP growth diagnostic carries long-duration sensitivity; the 2026-08-20 backup in long-end Treasury yields toward 20-month highs is the relevant macro axis, more so than any AI-capex datapoint.
• Biotech beta. Directionally tied to XBI/IBB risk appetite, with the qualification that Caris is a commercial-stage services business with a $1.03–1.04B revenue guide, not a clinical-stage binary.
• Uncorrelated driver. The dominant idiosyncratic input — MolDX and commercial payer coverage decisions, and the resulting ASP — has no linkage to the AI infrastructure trade that drives much of the market's headline flow.